The prognostic value of preoperative FDG-PET/CT metabolic parameters in cervical cancer patients

Abstract

Listen

Translate article

BackgroundTo explore quantitative metabolic and microstructural primary tumour parameters at pretreatment FDG-PET/CT and diffusion-weighted-magnetic resonance imaging (DW-MRI) in relation to clinical FIGO stage and outcome in uterine cervical cancer patients.MethodsFifty three patients with histopathologically verified cervical carcinoma with clinical FIGO stage IB1-IVA were subjected to FDG-PET/CT and subgroup also DW-MRI (n = 30) prior to treatment. Measurements from the FDG-PET/CT comprised lesion maximum-standardised uptake value (SUVmax), total lesion glycolysis (TLG) and metabolic tumour volume (MTV). In MR images longest-tumour-diameter (MRI-LD), tumour volume (MRI-TV) and mean tumour apparent-diffusion-coefficient (ADCmean) value were measured. FDG-PET/CT parameters were explored in relation to clinical prognostic factors at diagnosis and progression/recurrence free survival, and compared with the MRI parameters.ResultsThe metabolic tumour parameters TLG and MTV were highly positively correlated to MRI-LD and MRI-TV (rs = 072–0.82; p < 0.001 for all), whereas tumour SUVmax was only moderately correlated to MRI-LD (rs = 0.29; p ≤ 0.04) and MRI-TV (rs = 0.36; p ≤ 0.01). High tumour TLG, MTV, MRI-LD and MRI-TV predicted advanced FIGO stage, whereas high tumour SUVmax did not. No significant correlations were observed between tumour ADCmean and the other imaging parameters or FIGO stage. High primary tumour MTV (≥56.7 mL), high TLG (≥412 g) and large MRI-TV (≥36 mL) predicted reduced progression/recurrence free survival yielding corresponding hazard ratios [HR] of 7.8 (P = 0.002), 6.9 (P = 0.004) and 4.6 (P = 0.022), respectively. Also advanced FIGO stage (≥IIIA) was associated with reduced progression/recurrence free survival with HR of 6.9 (P = 0.004). In multivariable analysis, advanced FIGO stage (≥IIIA) and high MTV (≥56.7 mL) were independent prognostic factors with adjusted HRs of 5.5 (P = 0.020) and 7.8 (P = 0.025), respectively.ConclusionHigh MTV at pre-treatment FDG-PET/CT and high clinical FIGO stage independently predict reduced progression/recurrence free survival in cervical cancer patients.